These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 33183102)

  • 21. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase.
    Khan S; Attar F; Bloukh SH; Sharifi M; Nabi F; Bai Q; Khan RH; Falahati M
    Int J Biol Macromol; 2021 Jun; 181():605-611. PubMed ID: 33766591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Existing Drugs Considered as Promising in COVID-19 Therapy.
    Janik E; Niemcewicz M; Podogrocki M; Saluk-Bijak J; Bijak M
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34063964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs.
    Feng Z; Chen M; Xue Y; Liang T; Chen H; Zhou Y; Nolin TD; Smith RB; Xie XQ
    Brief Bioinform; 2021 Mar; 22(2):946-962. PubMed ID: 33078827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Target identification for repurposed drugs active against SARS-CoV-2 via high-throughput inverse docking.
    Ribone SR; Paz SA; Abrams CF; Villarreal MA
    J Comput Aided Mol Des; 2022 Jan; 36(1):25-37. PubMed ID: 34825285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Precision therapeutic targets for COVID-19.
    Krumm ZA; Lloyd GM; Francis CP; Nasif LH; Mitchell DA; Golde TE; Giasson BI; Xia Y
    Virol J; 2021 Mar; 18(1):66. PubMed ID: 33781287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposing anticancer drugs for the management of COVID-19.
    El Bairi K; Trapani D; Petrillo A; Le Page C; Zbakh H; Daniele B; Belbaraka R; Curigliano G; Afqir S
    Eur J Cancer; 2020 Dec; 141():40-61. PubMed ID: 33125946
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
    OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repurposing drugs for the management of COVID-19.
    Cusinato J; Cau Y; Calvani AM; Mori M
    Expert Opin Ther Pat; 2021 Apr; 31(4):295-307. PubMed ID: 33283567
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium.
    Gupta RK; Nwachuku EL; Zusman BE; Jha RM; Puccio AM
    PLoS One; 2021; 16(9):e0257784. PubMed ID: 34582497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
    Goel B; Bhardwaj N; Tripathi N; Jain SK
    Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
    Choudhury M; Dhanabalan AK; Goswami N
    J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.
    Pathak Y; Mishra A; Choudhir G; Kumar A; Tripathi V
    Pharmacol Rep; 2021 Jun; 73(3):926-938. PubMed ID: 33970450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress.
    Hossain MJ; Rahman SMA
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1009-1027. PubMed ID: 33355520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An overview on the use of antivirals for the treatment of patients with COVID19 disease.
    Malinis M; McManus D; Davis M; Topal J
    Expert Opin Investig Drugs; 2021 Jan; 30(1):45-59. PubMed ID: 33151781
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.
    Sanghai N; Shafiq K; Tranmer GK
    Mini Rev Med Chem; 2021; 21(1):3-9. PubMed ID: 32838716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.
    Paul SS; Biswas G
    Mini Rev Med Chem; 2021; 21(9):1123-1143. PubMed ID: 33355053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.
    Ashour NA; Abo Elmaaty A; Sarhan AA; Elkaeed EB; Moussa AM; Erfan IA; Al-Karmalawy AA
    Drug Des Devel Ther; 2022; 16():685-715. PubMed ID: 35321497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19.
    Apaydın ÇB; Çınar G; Cihan-Üstündağ G
    Curr Drug Targets; 2021; 22(17):1986-2005. PubMed ID: 33588727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Anatomy of the SARS-CoV-2 Biomedical Literature: Introducing the CovidX Network Algorithm for Drug Repurposing Recommendation.
    Gates LE; Hamed AA
    J Med Internet Res; 2020 Aug; 22(8):e21169. PubMed ID: 32735546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.